Roche's bevacizumab gets US FDA nod to treat the most common type of kidney cancer
Tuesday, August 04, 2009 09:00 IST Basel
Roche announced that the US Food and Drug Administration (FDA) has approved Avastin (bevacizumab) plus interferon alpha for people with metastatic renal cell carcinoma, the most common type of kidney cancer.
